Cardiol Therapeutics (CRDL)
(Delayed Data from NSDQ)
$1.98 USD
-0.05 (-2.46%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.98 USD
-0.05 (-2.46%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Zacks News
5 Small Drug Stocks to Buy From a Recovering Industry
by Kinjel Shah
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock
by Zacks Equity Research
Here we discuss some reasons why investing in Cardiol Therapeutics (CRDL) stock now may turn out to be a prudent move.
Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?
by Zacks Equity Research
Here we discuss why investing in Aurinia Pharmaceuticals (AUPH) stock now may be a prudent move.
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cardiol Therapeutics Inc. (CRDL) and DiaMedica Therapeutics, Inc. (DMAC) have performed compared to their sector so far this year.
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
by Zacks Equity Research
Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as Drug Industry Displays Strong Fundamentals
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.
Cardiol Therapeutics Inc. (CRDL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Cardiol Therapeutics Inc. (CRDL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Cardiol Therapeutics Inc. (CRDL) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Cardiol Therapeutics Inc. (CRDL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
by Zacks Equity Research
Here is how ANI Pharmaceuticals (ANIP) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.
Here's Why Cardiol Therapeutics Inc. (CRDL) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Cardiol Therapeutics Inc. (CRDL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Cardiol Therapeutics Inc. (CRDL) Could Find Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Cardiol Therapeutics Inc. (CRDL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.